Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus anlotinib first-line treatment for EGFR-mutant advanced NSCLC with co-mutations
ChiCTR2300070023Phase 2Recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Dongguan People's Hospital. Primary endpoint: Progression-free survival rate at 12 months. Started Jun 2021; status: recruiting.
02
Drugs
osimertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300070023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070023.